The CXCR4 antibody mediates CLL-B cell death via a bivalency-dependent mechanism, involving generation of reactive oxygen species (ROS), with no caspase activation requirement, reminiscent of PCD. This evidence concerns the gene CXCR4 and B-cell chronic lymphocytic leukemia.